NCT04116164View on ClinicalTrials.gov

Safety and Targeting of Anti-hk2 Antibody in mCRPC

EARLY_PHASE1TerminatedINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

September 18, 2019

Primary Completion Date

July 6, 2023

Study Completion Date

July 6, 2023

Conditions

Castration-Resistant Prostatic CancerMetastatic Disease

Interventions

DRUG

111In-DOTA-h11B6

4-6 mCi 111In labeled to 2 mg DOTA-h11B6; 0, 8 or 18 mg additional h11B6.

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Invicro

OTHER

collaborator

Janssen Research & Development, LLC

INDUSTRY

collaborator

Tomopath Inc.

INDUSTRY

lead

SpectronRX

INDUSTRY